U.S. Markets closed

Progenics Pharmaceuticals, Inc. (PGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.1000-0.4250 (-9.39%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.5250
Bid0.0000 x 3100
Ask0.0000 x 41800
Day's Range4.0100 - 4.7900
52 Week Range1.8900 - 6.3700
Avg. Volume1,874,252
Market Cap355.046M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateMay 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
  • Lantheus Holdings Inc (LNTH) Q2 2020 Earnings Call Transcript
    Motley Fool

    Lantheus Holdings Inc (LNTH) Q2 2020 Earnings Call Transcript

    Joining me today is our President and CEO, Mary Anne Heino, and our CFO, Bob Marshall. Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements due to a variety of risks and uncertainties.

  • Lantheus Completes Merger with Progenics
    Business Wire

    Lantheus Completes Merger with Progenics

    Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it has completed its previously announced merger with Progenics Pharmaceuticals, Inc. ("Progenics") (Nasdaq: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer. The merger agreement was first announced on October 2, 2019.

  • Independent Bank Group Set to Join S&P SmallCap 600
    PR Newswire

    Independent Bank Group Set to Join S&P SmallCap 600

    Independent Bank Group Inc. (NASD: IBTX) will replace Progenics Pharmaceuticals Inc. (NASD: PGNX) in the S&P; SmallCap 600 effective prior to the opening of trading on Monday, June 22. S&P; Small-Cap 600 constituent Lantheus Holdings Inc. (NASD: LNTH) is acquiring Progenics Pharmaceuticals in a deal expected to be completed on or about June 19 pending final conditions. Post-acquisition, Lantheus Holdings will remain in S&P; SmallCap 600.